YU Huan,SUN Yongkang,SONG Yanbo,et al.Treatment of Amyotrophic Lateral Sclerosis by the Method of Lifting the Sunken from "Deficiency,Toxin, Wind-Heat"[J].Journal of Traditional Chinese Medicine,2024,65(23):2476-2481.
YU Huan,SUN Yongkang,SONG Yanbo,et al.Treatment of Amyotrophic Lateral Sclerosis by the Method of Lifting the Sunken from "Deficiency,Toxin, Wind-Heat"[J].Journal of Traditional Chinese Medicine,2024,65(23):2476-2481.DOI: 10.13288/j.11-2166/r.2024.23.015.
Treatment of Amyotrophic Lateral Sclerosis by the Method of Lifting the Sunken from "Deficiency,Toxin, Wind-Heat"
is the combination of spleen-kidney qi and heart-lung
yang qi
in the chest, which is filled between the muscles and is able to maintain the normal shape of the muscles. Accordingly, it is proposed that the core pathogenesis of amyotrophic lateral sclerosis (ALS) is the deficiency sinking of general
qi
, with "deficiency" as the root, and "toxin" and "wind-heat" as the key factors for the rapid progression of the disease. The development process of ALS was classified into the initial onset stage, the increasingly progressive stage, and the rapid exacerbation stage, and differentiated and treated by deficiency, toxin, and wind-heat. Based on clinical experience, the wind medicinals were preferred. We formed self-prescribed
Juxian Decoction
(举陷汤) and modified from the perspective of "deficiency, toxicity, wind-heat" based on the wind medicinals of Huangqi (
Radix Astragali
), Shengma (
Actaea cimicifuga L.
), Chaihu (
Bupleurum spp.
) and so on. For the initial onset stage,
Yiqi Shengji Juxian Decoction
(益气生肌举陷汤),
Wenyang Liyan Juxian Decoction
(温阳利咽举陷汤) could be used; for the increasingly progressive stage,
Jiedu Juxian Decoction
(解毒举陷汤) could be used; for the rapid exacerbation stage,
Yinqiao Shufen Juxian Decoction
(银翘疏风举陷汤),
Yangxue Xifeng Juxian Decoction
(养血熄风举陷汤) could be used.
关键词
Keywords
references
FELDMAN EL , GOUTMAN SA , PETRI S , et al . Amyotrophic lateral sclerosis [J]. Lancet , 2022 , 400 ( 10360 ): 1363 - 1380 .
MASRORI P , VAN DAMME P . Amyotrophic lateral sclerosis: a clinical review [J]. Eur J Neurol , 2020 , 27 ( 10 ): 1918 - 1929 .
CHIÒ A , CALVO A , MOGLIA C , et al . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study [J]. J Neurol Neurosurg Psychiatry , 2011 , 82 ( 7 ): 740 - 746 .
BROWN RHJR , AL-CHALABI A . Amyotrophic lateral sclerosis [J]. N Engl J Med , 2017 , 377 ( 16 ): 1602 .
CHIÒ A , MAZZINI L , MORA G . Disease-modifying therapies in amyotrophic lateral sclerosis [J]. Neuropharmacology , 2020 , 167 : 107986 . doi: 10.1016/j.neuropharm. 2020.107986 http://dx.doi.org/10.1016/j.neuropharm.2020.107986 .
GOUTMAN SA , HARDIMAN O , AL-CHALABI A , et al . Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis [J]. Lancet Neurol , 2022 , 21 ( 5 ): 480 - 493 .
KIM G , GAUTIER O , TASSONI-TSUCHIDA E , et al . ALS genetics: gains, losses, and implications for future therapies [J]. Neuron , 2020 , 108 ( 5 ): 822 - 842 .
BRETTSCHNEIDER J , DEL TREDICI K , TOLEDO JB , et al . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis [J]. Ann Neurol , 2013 , 74 ( 1 ): 20 - 38 .
CEDARBAUM JM , STAMBLER N , MALTA E , et al . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase Ⅲ) [J]. J Neurol Sci , 1999 , 169 ( 1/2 ): 13 - 21 .